Search

23 Feb 2024: Search site. Office for Translational Research. poster_rcp_seminar_28nov20_-_vasculitis_and_lupus_resize2.jpg. 2024 University of Cambridge.

7 Jun 2024: basis.<br /> <strong>Dr David Jayne, Consultant in Nephrology and Vasculitis, Cambridge University Hospitals</strong><br /> David Jayne is an NHS consultant in nephrology and Director of the Vasculitis and Lupus ... biologic and other newer therapies in

6 Jun 2024: Whilst lupus can be controlled through lifestyle changes and medical interventions, there is currently no cure. ... potentialbr / long-term value.”/p pImmune-mediated diseases, such as inflammatory bowel disease, vasculitis and Lupus are common,

23 Feb 2024: Clinical evaluation of newer immunotherapeutics in vasculitis, lupus and immune-mediated renal disease. ... Co-ordination of international clinical research vasculitis network (EUVAS) and multi-centre randomised controlled trials.

7 Jun 2024: Prof David Jayne, Director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital. ... Targeting approaches for respiratory infection . David Fairen-Jimenez. Department of Chemical Engineering and Biotechnology.

23 Feb 2024: ANCA vasculitis and in kidney allograft rejection. ... Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis.

23 Feb 2024: Versus Arthritis Chair in Rheumatology. The McKinney lab uses a custom spotted oligo microarray platform to investigate gene expression signatures in autoimmune diseases, ANCA-associated systemic vasculitis and SLE. ... Professor of Clinical Autoimmunity.

23 Feb 2024: David Jayne. Evaluates immunotherapeutics in vasculitis, lupus and immune-mediated renal disease and co-ordinates the European Vasculitis Study Group (EUVAS) and multi-centre randomised controlled trials. ... Eoin McKinney. Investigates gene expression

23 Feb 2024: Professor of Clinical Autoimmunity, University of Cambridge. Director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital. ... Biomarker development. Proetomic and microbiomic studies in vasculitis and lupus nephritis and collaboration with

23 Feb 2024: Search site. Cambridge Immunology Network. Dr Lisa Willcocks. The vasculitis and lupus clinic specialises in looking after patients with diseases caused by an overactive immune system (autoimmune diseases). ... The most common of these diseases, that

23 Feb 2024: The Experimental Medicine and Immunotherapeutics division has a strong record in clinical research. ... Professor David Jayne : Director of the Vasculitis and Lupus Service, Addenbrooke’s Hospital.

23 Feb 2024: and Smith, K.G.C. “Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis.” Annals of the Rheumatic Diseases, 2010;69:1208-1213. ... and Salama, A.D.

23 Feb 2024: Wellcome Trust Senior Investigator. Honorary Consultant, Vasculitis and Lupus Clinic, Cambridge University Hospitals. ... FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted

22 Feb 2023: long-term value.”. Immune-mediated diseases, such as inflammatory bowel disease, vasculitis and Lupus are common, chronic and incurable, and there is currently no way of knowing whether a patient is ... I’m delighted to welcome Paul to the team and

23 Feb 2024: Prof Andrew Grace, Department of Biochemistry, University of Cambridge and Royal Papworth Hospital NHS Foundation Trust. - ... Prof David Jayne, Director of the Vasculitis and Lupus Service, Cambridge University Hospitals NHS Foundation Trust. -

uploads/2019/03/DavidJayne-HQ-819x1024.jpg 819w" sizes="(max-width: 240px) 100vw, 240px" //a/pnpClinical evaluation of newer immunotherapeutics in vasculitis, lupus and immune-mediated renal disease. ... Co-ordination of international clinical research

24 May 2013: David Jayne is an NHS consultant in nephrology and Director of the Vasculitis and Lupus unit at Addenbrooke’s Hospital, Cambridge. ... biologic and other newer therapies in vasculitis, systemic lupus erythematosus and Behcet’s disease.

7 Jun 2024: basis.<br /> <strong>Dr David Jayne, Consultant in Nephrology and Vasculitis, Cambridge University Hospitals</strong><br /> David Jayne is an NHS consultant in nephrology and Director of the Vasculitis and Lupus ... biologic and other newer therapies in

6 Jun 2024: causing proteins within tumour cells and trigger pathways to eliminate these proteins, thereby halting further growth of the tumour. ... potentialbr / long-term value.”/p pImmune-mediated diseases, such as inflammatory bowel disease, vasculitis and

7 Jun 2024: basis.<br /> <strong>Dr David Jayne, Consultant in Nephrology and Vasculitis, Cambridge University Hospitals</strong><br /> David Jayne is an NHS consultant in nephrology and Director of the Vasculitis and Lupus ... biologic and other newer therapies in